The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine–elicited human sera
Open accessPublished version of a preprint
Abstract
Vaccine protects against B1.1.7 variant: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B1.1.7 (VOC 202012/01) variant that emerged in late 2020 in the United Kingdom has many changes in the spike protein gene. Three of these are associated with enhanced infectivity and transmissibility, and there are concerns that B.1.1.7 might compromise the effectiveness of the vaccine. Muik et al. compared the neutralization efficacy of sera from 40 subjects immunized with the BioNTech-Pfizer mRNA vaccine BNT162b2 against a pseudovirus bearing the Wuhan reference strain or the lineage B.1.1.7 spike protein (see the Perspective by Altmann et al. ). Serum was derived from 40 subjects in two age groups 21 days after the booster shot. The vaccine remained effective against B.1.1.7 with a slight but significant decrease in neutralization that was more apparent in participants under 55 years of age. Thus, the vaccine provides a significant “cushion” of protection against this variant. Science , this issue p. 1152 ; see also p. 1103
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Together with recent reports of the preserved neutralization of SARS-CoV-2 with key S mutations found in the B.1.1.7 and the B.1.351lineage 39,40 , and neutralization of pseudovirus bearing the full set of mutations of B.1.1.7 S 41 , our data indicate broad BNT162b2-elicited immune recognition 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [39]
In the citing paper
“Neutralizing activity of the two mRNA vaccines against the B.1.351 variant has also been observed to be lower, by a factor of 8.6 (mRNA-1273 vaccine [Moderna]) or 6.5 (BNT-162b2 vaccine [Pfizer]) on pseudovirus neutralization assay, than activity against the D614G virus, whereas no difference was evident against the N510Y.V1 (B.1.1.7)–like mutant.19,28,29”
From Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [28]
In the citing paper
“As for the ramifications of our findings for the protective efficacy of current SARS-CoV-2 vaccines, the neutralizing activity of sera from vaccinated individuals against B.1.1.7 is largely intact and no adverse effects on current vaccines are expected (Fig. 4c), consistent with conclusions that were reached by other studies 34,40,41 .”
From Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7 (2021) · cites this paper as [41]
In the citing paper
“In general, the impact of B.1.1.7 mutations on neutralizing antibody titers is moderate.15, 16, 17, 18,20,24”
From Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals (2021) · cites this paper as [17]
In the citing paper
“Our finding that entry driven by the S protein of the B.1.1.7 variant can be efficiently inhibited by antibodies induced upon infection and vaccination is in agreement with those of Muik and colleagues, who reported that pseudoparticles bearing the B.1.1.7 S protein are efficiently neutralized by sera from BNT162b2-vaccinated individuals (Muik et al., 2021).”
From SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) · cites this paper as Muik et al., 2021
In the citing paper
“The Pfizer Cominarty (also termed BNT162b2) vaccine-elicited human sera neutralizes SARS-CoV-2 lineage B.1.1.7 pseudovirus, with slightly reduced titers in some vaccinees, when compared to the Wuhan reference strain 26,27 .”
From Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies (2021) · cites this paper as [26]
In the citing paper
“and to elicit strong antibody responses, effectively neutralizing the parental strain as well as diverse SARS-CoV-2 VOCs (13–15).”
From Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine–elicited human sera (2022) · cites this paper as [13]
In the citing paper
“The neutralization activity of sera collected from both mRNA-1273 and BNT162b2 vaccinated individuals was largely preserved against the B.1.1.7 variant relative to prior variants.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Self-citationStarr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · cited 1×
“One of these mutations, N501Y, was of particular concern because it is located in the receptor binding site, the spike with this mutation binds more tightly to its cellular receptor, ACE-2 (4); and virus with this mutation has an increased host range that includes mice (5).”
BackgroundMapping the Antigenic and Genetic Evolution of Influenza Virus
Smith, D. J., Lapedes, A. S., de Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2004) · Science · doi:10.1126/science.1097211 · Cited by 1,868
Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., O’Toole, Á., et al. (2021) · doi:10.1101/2020.12.30.20249034 · Cited by 1,611 · cited 1×
“7 was detected in the United Kingdom (2), and it subsequently increased in prevalence, showed enhanced transmissibility, and spread to other countries and continents (3).”
BackgroundAssessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England
The COVID-19 Genomics UK (COG-UK) consortium, Volz, E., Mishra, S., Chand, M., Barrett, J. C., Johnson, R., Geidelberg, L., Hinsley, W. R., Laydon, D. J., Dabrera, G., et al. (2021) · Nature · doi:10.1038/s41586-021-03470-x · Cited by 1,611
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914 · cited 2×
“Further, 19 pseudoviruses, each bearing a SARS-CoV-2 S with a different mutation found in circulating strains, were also neutralized as efficiently as nonmutant SARS-CoV-2 S bearing pseudoviruses by BNT162b2-immune sera (7).”
BackgroundMethodSelf-citationAdaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy
Gu, H., Chen, Q., Yang, G., He, L., Fan, H., Deng, Y.-Q., Wang, Y., Teng, Y., Zhao, Z., Cui, Y., et al. (2020) · Science · doi:10.1126/science.abc4730 · Cited by 762 · cited 1×
“One of these mutations, N501Y, was of particular concern because it is located in the receptor binding site, the spike with this mutation binds more tightly to its cellular receptor, ACE-2 (4); and virus with this mutation has an increased host range that includes mice (5).”
BackgroundBNT162b vaccines protect rhesus macaques from SARS-CoV-2
Vogel, A. B., Kanevsky, I., Che, Y., Swanson, K. A., Muik, A., Vormehr, M., Kranz, L. M., Walzer, K. C., Hein, S., Güler, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03275-y · Cited by 694
Self-citationCase, J. B., Rothlauf, P. W., Chen, R. E., Liu, Z., Zhao, H., Kim, A. S., Bloyet, L.-M., Zeng, Q., Tahan, S., Droit, L., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.06.021 · Cited by 410
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–300 of 518
What We Do Know and Do Not Yet Know about COVID-19 Vaccines as of the Beginning of the Year 2021
Yoo, J. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e54 · Cited by 33
The Immune Response to SARS-CoV-2 and Variants of Concern
Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 36
“6-fold reduction in neutralisation of alpha variant and the ancestral strain by post vaccination (BNT162b2) sera [66,67,69,71,72].”
BackgroundGorchakov, A. A., Kulemzin, S. V., Guselnikov, S. V., Baranov, K. O., Николаевна, Б. Т., Mechetina, L. V., Volkova, O. Y., Najakshin, A. M., Chikaev, N. A., Chikaev, A. N., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00340-8 · Cited by 33
Immune response against SARS-CoV-2 variants: the role of neutralization assays
Chmielewska, A., Czarnota, A., Bieńkowska-Szewczyk, K., & Grzyb, K. (2021) · npj Vaccines · doi:10.1038/s41541-021-00404-6 · Cited by 34
The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines
Jiang, Y., Wu, Q. Y., Song, P., & You, C. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2021.806641 · Cited by 34
“It is worth noting that the nucleotide substitution of G23012A in the Beta variant participated in the E484Kmutation, considered to involve in altering viral antigenicity and in turn causing low efficacy of vaccines (44, 47, 48).”
BackgroundThe SARS-CoV-2 Delta variant is poised to acquire complete resistance to wild-type spike vaccinesPreprint
Liu, Y., Arase, N., Kishikawa, J.-I., Hirose, M., Li, S., Tada, A., Matsuoka, S., Arakawa, A., Akamatsu, K., Ono, C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.22.457114 · Cited by 31
“Considering the fact that most VOCs have completely escaped from anti-NTD neutralizing antibodies regardless of the fact that the neutralizing efficiency is quite low compared to anti-RBD neutralizing antibodies in vitro, SARS-CoV-2 infection mediated by the NTD through L-SIGN or other unknown receptors may play a mor…”
BackgroundInfluentialGidari, A., Sabbatini, S., Bastianelli, S., Pierucci, S., Busti, C., Monari, C., Pasqua, B. L., Dragoni, F., Schiaroli, E., Zazzi, M., et al. (2021) · Journal of Infection · doi:10.1016/j.jinf.2021.07.019 · Cited by 34
Wang, K., Wang, L., Li, M., Xie, B., He, L., Wang, M., Zhang, R., Hou, N., Zhang, Y., & Jia, F. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.820544 · Cited by 33
Role of artificial intelligence in peptide vaccine design against RNA viruses
Mohanty, E., & Mohanty, A. (2021) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2021.100768 · Cited by 34
Advances in mRNA and other vaccines against MERS-CoV
Tai, W., Zhang, X., Yang, Y., Zhu, J., & Du, L. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.007 · Cited by 36
Muik, A., Lui, B. G., Quandt, J., Diao, H., Fu, Y., Bacher, M., Gordon, J., Toker, A., Grosser, J., Ozhelvaci, O., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112888 · Cited by 37
Self-citationRöltgen, K., Nielsen, S. C. A., Arunachalam, P. S., Yang, F., Hoh, R. A., Wirz, O. F., Lee, A. S., Gao, F., Mallajosyula, V., Li, C., et al. (2021) · doi:10.1101/2021.04.05.21254952 · Cited by 45
“…B.1.1.7, first detected in September 2020 in the UK, is reported to give a 20% 231 reduction of antibody titers in serum samples from vaccinees (Muik et al., 2021), but the ChAdOx1 232 vaccine based on Wuhan-Hu-1-like S antigen showed similar efficacy for earlier circulating 233 viruses and…”
MethodInfluentialKuzmina, A., Wattad, S., Khalaila, Y., Ottolenghi, A., Rosental, B., Engel, S., Rosenberg, E., & Taube, R. (2021) · iScience · doi:10.1016/j.isci.2021.103467 · Cited by 33
“…331–528) attaches the human angiotensin-converting enzyme 2 (ACE2) receptor to mediate viral cell attachment and entry (Bestle et al., 2020; Hoffmann et al., 2020a, 2020b; Johnson et al., 2021; Letko et al., 2020; Papa et al., 2021; Walls et al., 2020; Wrapp et al., 2020; Zang et al., 2020).”
Stankov, M. V., Cossmann, A., Bonifacius, A., Dopfer‐Jablonka, A., Ramos, G. M., Gödecke, N., Scharff, A. Z., Happle, C., Boeck, A.-L., Tran, A. T., et al. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab555 · Cited by 31
Olsen, R. J., Christensen, P. A., Long, S. W., Subedi, S., Hodjat, P., Olson, R., Nguyen, M., Davis, J. J., Yerramilli, P., Saavedra, M. O., et al. (2021) · American Journal Of Pathology · doi:10.1016/j.ajpath.2021.07.002 · Cited by 30
Ecological and evolutionary dynamics of multi-strain RNA viruses
Makau, D. N., Lycett, S., Smith, M. J., Paploski, I. A. D., Cheeran, M. C. ‐., Craft, M. E., Kao, R. R., Schroeder, D. C., Doeschl‐Wilson, A., & VanderWaal, K. L. (2022) · Nature Ecology & Evolution · doi:10.1038/s41559-022-01860-6 · Cited by 35
The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19
An, X., Duan, L., Zhang, Y. H., Jin, D., Zhao, S., Zhou, R., Duan, Y., Lian, F., & Tong, X. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00454-x · Cited by 30
“7 does not escape the protection mediated by the Pfizer-BioNTech BNT162b2 COVID-19 vaccine [57].”
BackgroundSalazar–García, M., Acosta-Contreras, S., Martinez, G. R., Cruz‐Rangel, A., Flores-Alanis, A., Patiño‐López, G., & Luna-Pineda, V. M. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.817200 · Cited by 29
“…antibody titers of vaccinated persons to evaluate if vaccinations provide enough protection against SARS-CoV-2 VOC infection (Table 2; Collier et al., 2021; Ikegame et al., 2021; McCallum et al., 2021; Muik et al., 2021; Shen et al., 2021a,b; Wang G.-L. et al., 2021; Wang P. et al., 2021).”
BackgroundZhang, J., Han, Z. B., Liang, Y., Zhang, X. F., Jin, Y. Q., Du, L. F., Shao, S., Wang, H., Hou, J. W., Xu, K., et al. (2022) · eLife · doi:10.7554/elife.78633 · Cited by 29
Gorman, M. J., Patel, N., Guebre‐Xabier, M., Zhu, A. L., Atyeo, C. G., Pullen, K. M., Loos, C., Goez-Gazi, Y., Carrion, R., Tian, J.-H., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.05.429759 · Cited by 29
Clinical challenges of SARS‑CoV‑2 variants (Review)
Cojocaru, C., Cojocaru, E., Turcanu, A., & Zaharia, D. C. (2022) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2022.11343 · Cited by 29
“Current data suggest that protection for the Alpha variant induced by Pfizer‐BioNTech vaccine is similar to that for wild‐type SARS‐CoV‐2 virus, but is significantly lower for Beta, Gamma and Delta variants (65,66).”
BackgroundHumoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis
Lee, E.-J., & Oh, J. E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0075 · Cited by 30
“…the efficacy of the vaccines against them was tested, revealing high efficacy against D614G (Europe) (Garcia-Beltran et al., 2021b; Mahase, 2021; Muik et al., 2021), B.1.1.7 (UK) (Garcia-Beltran et al., 2021b; Heath et al., 2021; Hoffmann et al., 2021; Muik et al., 2021; Wang et al., 2021b; Wu…”
BackgroundResultInfluentialChen, H.-Y., Huang, C., Tian, L., Huang, X., Zhang, C., Llewellyn, G. N., Rogers, G. L., Andresen, K., O’Gorman, M. R. G., Chen, Y., et al. (2021) · Journal of Virology · doi:10.1128/jvi.00966-21 · Cited by 31
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · medRxiv · doi:10.1101/2021.03.31.21254660 · Cited by 30
Chen, Y., Yang, W., Chen, H., Huang, L., Gao, J.-Y., Lin, C., Wang, Y.-C., Yang, C., Liu, Y., Hou, M., et al. (2022) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2022.101658 · Cited by 30
“Accordingly, P fi zer utilized vaccine (BNT162b2)-induced human sera to neutralize SARS-CoV-2 lineage B.1.1.7 pseudovirus, with slightly reduced activity compared with the original strain (21).”
InfluentialNucleoside‐modified messenger RNA COVID‐19 vaccine platform
Roncati, L., & Corsi, L. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26924 · Cited by 28
“202012/01 and the declared results have been encouraging, since the vaccine‐elicited sera have maintained a neutralizing power.(17)”
ResultKaku, Y., Kuwata, T., Zahid, H. M., Hashiguchi, T., Noda, T., Kuramoto, N., Biswas, S., Matsumoto, K., Shimizu, M., Kawanami, Y., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109385 · Cited by 26
Noor, R., Shareen, S., & Billah, M. (2022) · Bulletin of the National Research Centre/Bulletin of the National Research Center · doi:10.1186/s42269-022-00787-z · Cited by 29
Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
Forni, D., Cagliani, R., Arrigoni, F., Benvenuti, M., Mozzi, A., Pozzoli, U., Clerici, M., GIOIA, L. D., & Sironi, M. (2021) · Virus Evolution · doi:10.1093/ve/veab061 · Cited by 30
Bai, J., Chiba, A., Murayama, G., Kuga, T., Tamura, N., & Miyake, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.786586 · Cited by 27
Research progress on vaccine efficacy against SARS-CoV-2 variants of concern
Bian, L., Liu, J., Gao, F., Gao, Q., He, Q., Mao, Q., Wu, X., Xu, M., & Liang, Z. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2057161 · Cited by 30
The role of pseudotype neutralization assays in understanding SARS CoV-2
Cantoni, D. M., Neto, M. M., & Temperton, N. J. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab005 · Cited by 27
Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variantsPreprint
Ikegame, S., Siddiquey, M. N. A., Hung, C.-T., Haas, G. D., Brambilla, L., Oguntuyo, K. Y., Kowdle, S., Vilardo, A. E., Edelstein, A., Perandones, C., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-400230/v1 · Cited by 27
“…shows enhanced transmissibility and more severe disease outcomes(Davies, Abbott, et al. , 2021; Davies, Jarvis, et al. , 2021), it does not appear to be particularly more resistant to serum neutralizing responses elicited by vaccines or natural infection (Muik et al. , 2021; Shen et al. , 2021).”
Ratcliff, J., Nguyen, D. V., Fish, M., Rynne, J., Jennings, A., Williams, S. V., Al-Beidh, F., Bonsall, D., Evans, A. L., Golubchik, T., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab283 · Cited by 27
“For example, emerging SARS-CoV-2 variants have been associated with reduced susceptibility to neutralization [12, 21, 24] and greater pathogenicity [20, 25], and potentially greater resistance to immunotherapy.”
Rapid test to assess the escape of SARS-CoV-2 variants of concern
Heggestad, J. T., Britton, R. J., Kinnamon, D., Wall, S. A., Joh, D. Y., Hucknall, A., Olson, L. B., Anderson, J. G., Mazur, A., Wolfe, C. R., et al. (2021) · Science Advances · doi:10.1126/sciadv.abl7682 · Cited by 25
“Fortunately, several studies have shown that convalescent and vaccinee sera effectively cross-neutralize B.1.1.7 with only a minimal decrease in potency ( 11 – 14 ).”
InfluentialMolecular Beacons Allow Specific RT-LAMP Detection of B.1.1.7 Variant SARS-CoV-2
Sherrill-Mix, S. A., Duyne, G. D. V., & Bushman, F. D. (2021) · Journal of Biomolecular Techniques JBT · doi:10.7171/jbt.21-3203-004 · Cited by 26
Fernández, J., Bruneau, N., Fasce, R., Martín, H. S., Balanda, M., Bustos, P., Ulloa, S., Mora, J., & Ramírez, E., V (2021) · Journal of Medical Virology · doi:10.1002/jmv.27310 · Cited by 25
Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges
Kandimalla, R. J. L., Chakraborty, P., Vallamkondu, J., Chaudhary, A., Samanta, S., Reddy, P. H., Feo, V. D., & Dewanjee, S. (2021) · Biomedicines · doi:10.3390/biomedicines9111740 · Cited by 25
Antibody-mediated immunity to SARS-CoV-2 spike
Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 22
“…D614G variant, B.1.1.7 also displayed slightly increased resistance to neutralization by polyclonal sera from convalescent patients and vaccinees (Muik et al., 2021; Shen et al., 2021; Supasa et al., 2021), although this resistance was not great enough to cause significant breakthrough infection…”
InfluentialA comparison between SARS-CoV-1 and SARS-CoV2: an update on current COVID-19 vaccines
Abdolmaleki, G., Taheri, M. A., Paridehpour, S., Mohammadi, N. M., Tabatabaei, Y. A., Mousavi, T., & Amin, M. (2022) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-022-00446-8 · Cited by 26
Rabaan, A. A., Al-Ahmed, S. H., Albayat, H., Alwarthan, S. M., Alhajri, M. M., Najim, M. A., Alshehail, B. M., Al-Adsani, W., Alghadeer, A., Abduljabbar, W. A., et al. (2023) · Medicina · doi:10.3390/medicina59030507 · Cited by 26
Kalkeri, R., Cai, Z., Lin, S., Farmer, J., Kuzmichev, Y. V., & Koide, F. (2021) · Microorganisms · doi:10.3390/microorganisms9081744 · Cited by 25
Netzl, A., Türeli, S., LeGresley, E. B., Mühlemann, B., Wilks, S., & Smith, D. J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.31.474032 · Cited by 25
SARS-CoV-2 variants: A double-edged sword?
Jogalekar, M. P., Veerabathini, A., & Gangadaran, P. (2021) · Experimental Biology and Medicine · doi:10.1177/15353702211014146 · Cited by 24
The challenge of emerging SARS-CoV-2 mutants to vaccine development
Li, R., Liu, J., & Zhang, H. (2021) · Journal of genetics and genomics/Journal of Genetics and Genomics · doi:10.1016/j.jgg.2021.03.001 · Cited by 25
Zhao, S., Lou, J., Chong, K. C., Cao, L., Zheng, H., Chen, Z., Chan, R. W. Y., Zee, B. C.-Y., Chan, P. K. S., & Wang, M. H. (2021) · Viruses · doi:10.3390/v13040638 · Cited by 23
Hogan, C. A., Jassem, A. N., Sbihi, H., Joffres, Y., Tyson, J. R., Noftall, K., Taylor, M., Lee, T., Fjell, C. D., Wilmer, A., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2711.211190 · Cited by 24
Jutel, M., Torres, M. J., Palomares, Ó., Akdiş, C. A., Eiwegger, T., Untersmayr, E., Barber, D., Zemelka‐Wiącek, M., Kosowska, A., Palmer, E. N., et al. (2022) · Allergy · doi:10.1111/all.15252 · Cited by 25
Grimaldi, A., Panariello, F., Annunziata, P., Giuliano, T., Daniele, M., Pierri, B., Colantuono, C., Salvi, M., Bouchè, V., Manfredi, A., et al. (2022) · Genome Medicine · doi:10.1186/s13073-022-01098-8 · Cited by 26
“Although VOC are still responsive to current treatments as the ancestral virus does [9], some standalone SNPs such as the Spike mutation E484K, cause a lower sensitivity to both monoclonal antibodies and vaccine-induced human serum [10, 11].”
BackgroundAlam, A. S. M. R. U., Islam, O. K., Hasan, M. S., Islam, M. R., Mahmud, S., Al‐Emran, H. M., Jahid, I. K., Crandall, K. A., & Hossain, M. A. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27416 · Cited by 24
Schardt, J. S., Pornnoppadol, G., Desai, A. A., Park, K. S., Zupancic, J. M., Makowski, E. K., Smith, M. D., Chen, H., Barbosa, M. G. D. M., Cascalho, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99401-x · Cited by 23
An overview of the ongoing challenges in SARS-CoV-2 global control
Shehata, A. A., Parvin, R., Nagy, A., Wang, Y., Azhar, T. M., Attia, Y. A., Azhar, E. I., Paul, A. K., & Rahmatullah, M. (2021) · German Journal of Microbiology · doi:10.51585/gjm.2021.2.0006 · Cited by 24
Multiplex Fragment Analysis for Flexible Detection of All SARS-CoV-2 Variants of Concern
Clark, A. E., Wang, Z., Ostman, E., Zheng, H., Yao, H., Cantarel, B. L., Kanchwala, M., Xing, C., Chen, L., Irwin, P., et al. (2022) · Clinical Chemistry · doi:10.1093/clinchem/hvac081 · Cited by 23
“Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) have emerged harboring epidemiologically significant genetic mutations impacting transmission kinetics (1), vaccine responses (2, 3), mortality (4, 5), and monoclonal antibody therapy (3, 6–9).”
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2022) · Vaccines · doi:10.3390/vaccines10081251 · Cited by 22
Barghash, R. F., Gemmati, D., Awad, A. M., Elbakry, M. M. M., Tisato, V., Awad, K., & Singh, A. V. (2024) · Molecules · doi:10.3390/molecules29235564 · Cited by 24
“…to some monoclonal antibody therapies [57,58], mRNA vaccines (Moderna’s mRNA-1273 and Pfizer-BioNTech’s BNT162b2) remained highly effective [59,60]. of However, inactivated-virus vaccines like BBV152/COVAXIN (Bharat Biotech) and BBIBP-CorV (Sinopharm) [61,62] demonstrated reduced neutralizing…”
Previous SARS-CoV-2 Infection Increases B.1.1.7 Cross-Neutralization by Vaccinated Individuals
Trinité, B., Pradenas, E., Marfil, S., Rovirosa, C., Urrea, V., Tarrés-Freixas, F., Ortiz, R., Rodon, J., Vergara‐Alert, J., Segalés, J., et al. (2021) · Viruses · doi:10.3390/v13061135 · Cited by 20
The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom
Wu, J., Zhang, L., Zhang, Y., Wang, H., Ding, R., Nie, J., Li, Q., Liu, S., Yu, Y., Yang, X., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.687869 · Cited by 23
“Since December 2020, the VOC-202012/01 (VOC202012/01 variant, including multiple mutations 69-70del, 144/ 145del, N501Y, A570D, P681H, T716I, S982A, and D1118H) has been increasing rapidly.”
BackgroundResultInfluentialPani, A., Cento, V., Vismara, C., Campisi, D., Ruscio, F. D., Romandini, A., Senatore, M., Schenardi, P. A., Gagliardi, O. M., Giroldi, S., et al. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2021.08.013 · Cited by 22
COVID-19 Vaccine: Between Myth and Truth
Piccaluga, P. P., Guardo, A. D., Lagni, A., Lotti, V., Diani, E., Navari, M., & Gibellini, D. (2022) · Vaccines · doi:10.3390/vaccines10030349 · Cited by 22
“7 mutations, and even though there was a slight reduction, the Pfizer-BioNTech vaccine was found to be more than 90% effective against symptomatic infection from the Alpha variant [96].”
BackgroundmRNA delivery technologies: Toward clinical translation
Gómez-Aguado, I., Rodríguez-Castejón, J., Beraza-Millor, M., Rodríguez‐Gascón, A., del Pozo‐Rodríguez, A., & Solinís, M. Á. (2022) · International review of cytology · doi:10.1016/bs.ircmb.2022.04.010 · Cited by 23
A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus
Wang, Z., Li, Z., Shi, W., Zhu, D., Hu, S., Dinh, P., & Cheng, K. (2023) · Science Advances · doi:10.1126/sciadv.abo4100 · Cited by 22
The importance of genomic analysis in cracking the coronavirus pandemic
Zella, D., Giovanetti, M., Cella, E., Borsetti, A., Ciotti, M., Ceccarelli, G., d’Ettorre, G., Pezzuto, A., Tambone, V., Campanozzi, L. L., et al. (2021) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2021.1917998 · Cited by 23
Influenza Virus and SARS-CoV-2 Vaccines
Sandor, A., Sturdivant, M. S., & Ting, J. P. ‐. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001287 · Cited by 23
Wang, Y., Yan, A., Song, D., Dong, C., Rao, M., Gao, Y., Qi, R., Ma, X., Wang, Q., Xu, H., et al. (2023) · Cell Discovery · doi:10.1038/s41421-022-00509-9 · Cited by 21
Loconsole, D., Sallustio, A., Accogli, M., Leaci, A., Sanguedolce, A., Parisi, A., & Chironna, M. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.007 · Cited by 20
Potential transmission chains of variant B.1.1.7 and co-mutations of SARS-CoV-2
Zhang, J., Zhang, Y., Kang, J.-Y., Chen, S., He, Y. O., Han, B., Liu, M., Lu, L., Li, L., Yi, Z., et al. (2021) · Cell Discovery · doi:10.1038/s41421-021-00282-1 · Cited by 19
Tober‐Lau, P., Schwarz, T., Hillus, D., Spieckermann, J., Helbig, E. T., Lippert, L. J., Thibeault, C., Koch, W., Bergfeld, L., Niemeyer, D., et al. (2021) · Emerging infectious diseases · doi:10.3201/eid2708.210887 · Cited by 20
“7 in cell culture (7), but observational data from Israel suggest BNT162b2 vaccination is effective against B.”
BackgroundXiao, C., Mao, L., Wang, Z., Gao, L., Zhu, G., Su, J., Chen, X., Yuan, J., Hu, Y., Yin, Z., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103934 · Cited by 21
“With the ongoing spreading of the virus all over the world, the genetic evolution in SARS-CoV-2 continues to provide the opportunities for the virus to obtain mutations which might contribute to the changes in viral transmissibility, infectivity, pathogenesis and even immune evasion(Neches et al., 2021; Rashid et al.,…”
BackgroundCantoni, D. M., Neto, M. M., Nadesalingam, A., Wells, D. A., Carnell, G., Ohlendorf, L., Ferrari, M., Palmer, P., Chan, A. C. Y., Smith, P., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.773982 · Cited by 20
Sharma, S., Vercruysse, T., Sánchez-Felipe, L., Kerstens, W., Rasulova, M., Bervoets, L., Keyzer, C. D., Abdelnabi, R., Foo, C. S.-Y., Lemmens, V., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34439-7 · Cited by 24
Coronavirus Disease (COVID)-19 and Diabetic Kidney Disease
Srivastava, S. P., Srivastava, R., Chand, S., & Goodwin, J. E. (2021) · Pharmaceuticals · doi:10.3390/ph14080751 · Cited by 20
The Value of Rapid Antigen Tests for Identifying Carriers of Viable SARS-CoV-2
Shidlovskaya, E. V., Kuznetsova, N. A., Divisenko, E. V., et al. (2021) · Viruses · doi:10.3390/v13102012 · Cited by 19
Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines
Hofman, K., Shenoy, G. N., Chak, V., & Balu‐Iyer, S. V. (2021) · Immunological Investigations · doi:10.1080/08820139.2021.1904977 · Cited by 20
“…assessing neutralizing activity of mRNA vaccinated patient plasma towards emerging variants has shown 79% neutralizing ability towards the B.1.1.7 variant compared to wild-type, signifying a reduced but still prevalent neutralizing ability toward the variant (Muik et al. 2021; Wang et al. 2021).”
BackgroundInfluentialSARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition
Altmann, D. M., Reynolds, C. J., & Boyton, R. J. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100286 · Cited by 19
“7 mutations on neutralization.(10) However, reports on neutralization of the other variants suggest a significant ablation of spike recognition.”
SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19
Hirsch, C., Valk, S. J., Piechotta, V., Chai, K. L., Estcourt, L. J., Monsef, I., Salomon, S., Tomlinson, E., Popp, M., Wood, E. M., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd014945 · Cited by 19
Li, R., Li, Y., Zou, Z., Liu, Y., Li, X., Zhuang, G., Shen, M., & Zhang, L. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2021.801763 · Cited by 20
SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants
Khamees, A., Bani-Issa, J., Zoubi, M. S. A., Qasem, T., Alarjah, M. I. A., Alawadin, S. A., Al‐Shami, K., Hussein, F. H., Hussein, E. I., Bashayreh, I. H., et al. (2022) · Pathogens · doi:10.3390/pathogens11020275 · Cited by 19
Roth, N., Schön, J., Hoffmann, D., Thran, M., Thess, A., Mueller, S. O., Petsch, B., & Rauch, S. (2021) · doi:10.1101/2021.05.13.443734 · Cited by 18
Wu, T., Kang, S., Peng, W., Zuo, C., Zhu, Y., Pan, L., Fu, K., You, Y., Yang, X., Luo, X., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.702066 · Cited by 21
“7 lineage by BNT162b2-immune sera made it unlikely to escape from BNT162b2-mediated protection (175).”
BackgroundKhan, A., Khan, S., Ahmad, S., Anwar, Z., Hussain, Z., Safdar, M. M., Rizwan, M., Waseem, M., Hussain, A., Akhlaq, M., et al. (2021) · Microbial Pathogenesis · doi:10.1016/j.micpath.2021.105161 · Cited by 18
Wang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., Loh, C. Y., Fong, S., Hartley, C. S., Tan, S. Y., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00389-2 · Cited by 19
Wu, J., Nie, J., Zhang, L., Song, H., An, Y., Liang, Z., Yang, J., Ding, R., Liu, S., Li, Q., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00874-7 · Cited by 18
Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
Ju, B., Zhou, B., Song, S., Fan, Q., Ge, X., Wang, H., Cheng, L., Guo, H., Shu, D., Liu, L., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.732 · Cited by 17
Grieco, T., Ambrosio, L., Trovato, F., Vitiello, M., Demofonte, I., Fantò, M., Paolino, G., & Pellacani, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11071822 · Cited by 19
“The majority of these symptoms are reported as mild and transient, occurring mostly after the second dose [12,13].”
BackgroundResultInfluentialHigashimoto, Y., Kozawa, K., Miura, H., Kawamura, Y., Ihira, M., Hiramatsu, H., Suzuki, R., Haga, K., Takai‐Todaka, R., Sawada, A., et al. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2105611 · Cited by 18
A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants
Rabaan, A. A., Mutair, A. S. A., Hajissa, K., Alfaraj, A. H., Al-Jishi, J. M., Alhajri, M. M., Alwarthan, S. M., Alsuliman, S. A., Al-Najjar, A. H., Al-Zaydani, I. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101655 · Cited by 18
“However, the Biontech/Pfizer and Moderna mRNA vaccines were able to lower the infectivity of the Alpha versions [4,133].”
BackgroundPhylogenomic Evidence of Reinfection and Persistence of SARS-CoV-2: First Report from Colombia
Ramírez, J. D., Muñoz, M., Ballesteros, N., Patiño, L. H., Castañeda, S., Rincón, C. A., Méndez, C., Oliveros, C., Perez, J., Márquez, E. K., et al. (2021) · Vaccines · doi:10.3390/vaccines9030282 · Cited by 16
Lin, H., Chen, C.-C., Chiao, D.-J., Chang, T.-Y., Chen, X.-A., Young, J., & Kuo, S.-C. (2021) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2021.11.020 · Cited by 17
Verkhivker, G. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23062928 · Cited by 17
Yeung, P. S.-W., Wang, H., Sibai, M., Solis, D., Yamamoto, F. F., Iwai, N., Jiang, B., Hammond, N. A., Truong, B., Bihon, S., et al. (2022) · Journal of Clinical Microbiology · doi:10.1128/jcm.00178-22 · Cited by 18
Zecca, E., Rizzi, M., Tonello, S., Matino, E., Costanzo, M., Rizzi, E., Casciaro, G. F., Manfredi, G. F., Acquaviva, A., Gagliardi, I., et al. (2022) · Viruses · doi:10.3390/v14081766 · Cited by 17
Ruiz, M. J., Siracusano, G., Cottignies-Calamarte, A., Tudor, D., Real, F., Zhu, A., Pastori, C., Capron, C., Rosenberg, A. R., Temperton, N. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.842468 · Cited by 21
“Altogether, this set of results suggested that a previous severe COVID-19 might confer cross-protection to re-infection with at least the Alpha, Beta, and Gamma variants at the site of viral entry, in agreement with the epidemiological data recorded and mentioned earlier (44, 45).”
ResultPicazo, J. J. (2021) · Revista Española de Quimioterapia · doi:10.37201/req/085.2021 · Cited by 22
Verkhivker, G. M., Agajanian, S., Kassab, R., & Krishnan, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084376 · Cited by 18
COVID-19 vaccines: A race against time
Peiffer‐Smadja, N., Rozencwajg, S., Kherabi, Y., Yazdanpanah, Y., & Montravers, P. (2021) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2021.100848 · Cited by 16
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
Liang, H., Wu, Y., Yau, V., Yin, H.-X., Lowe, S., Bentley, R., Ahmed, M. A., Zhao, W., & Sun, C. (2022) · Vaccines · doi:10.3390/vaccines10091538 · Cited by 16
“In addition, the E484K mutation in the Beta variant includes a nucleotide substitution of G23012A, which is thought to be involved in altering the antigenicity of the virus, resulting in a less effective vaccine [24,27,33].”
BackgroundEfficacy and Safety of COVID-19 Vaccines—An Update
Sharma, E., Revinipati, S., Bhandari, S., Thakur, S., Goyal, S., Ghose, A., Bajpai, S., Muhammad, W., & Boussios, S. (2022) · Diseases · doi:10.3390/diseases10040112 · Cited by 17
Yang, Z., Zhang, J., Gao, S., & Wang, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19020689 · Cited by 16
“As a result, the development of vaccines has become an important focus [4,5].”
BackgroundWang, W., Chen, Y., Su, W., Liu, Y., Shen, W., Chang, W., Huang, S., Lin, C., Wang, Y., Yang, C., et al. (2022) · Journal of Food Biochemistry · doi:10.1111/jfbc.14354 · Cited by 15
“Another mRNA vaccine (BNT162b2, Pfizer) was found to produce reduced neutralizing titers against the Alpha (B.1.1.7) (Muik et al., 2021), Delta (B.1.617.2) (Planas et al., 2021), and Omicron (B.1.1.529) (Garcia- Beltran et al., 2022) variants in immune sera.”
BackgroundInfluentialHui, A., Li, J., Zhu, L., Tang, R., Ye, H., Lin, M., Ge, L., Wang, X., Peng, F., Wu, Z., et al. (2022) · The Lancet Regional Health - Western Pacific · doi:10.1016/j.lanwpc.2022.100586 · Cited by 19
Self-citation
Metadata
- Authors
- Muik, A., Wallisch, A.-K., Sänger, B., Swanson, K. A., Mühl, J., Chen, W., Cai, H., Maurus, D., Sarkar, R., Türeci, Ö., Dormitzer, P. R., & Şahin, U.
- Affiliations
- BioNTech (Germany) (DE)
- Pfizer (United States) (US)
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Şahin, Uğur
- ORCID
- Venue
- Science
- Published
- 2021-03-12
- Volume
- 371
- Issue
- 6534
- Pages
- 1152-1153
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7971771
- OpenAlex
- W3123108673
- Semantic Scholar
- a28b6633cf65c49f1251702b8e3e3c1b85e19236
- Cited by
- 515
- References
- 12
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 17 · 2023: 34 · 2022: 152 · 2021: 298
- FWCI
- 39.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Keywords
- SARS-CoV-2, B.1.1.7 lineage, BNT162b2, mRNA vaccines, neutralizing antibodies, spike protein mutations, vaccine escape, pseudovirus neutralization
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, BNT162 Vaccine, Adult, Aged, Antibodies, Viral, China, Female, United Kingdom, Humans, Male, Middle Aged, Neutralization Tests, Young Adult, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
